Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance

Neuroscience Letters

Volumn 406, Issue 3, 2006, Pages 189-193

  Liu, Gang ^a   Men, Ping ^a   Harris, Peggy L R ^b   Rolston, Raj K ^b   Perry, George ^b,c   Smith, Mark A ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c University of San Antonio   (United States)

Author keywords

Blood brain barrier crossing; Chelator nanoparticle conjugation; Lipoprotein absorption; Metal dysregulation; Neurodegeneration disease; Targeting chelation therapy

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHELATING AGENT; DRUG CARRIER; IRON; LOW DENSITY LIPOPROTEIN; METAL COMPLEX; NANOPARTICLE;

ADSORPTION; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CHOLESTEROL TRANSPORT; CONJUGATION; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; IRON CHELATION; NEUROLOGIC DISEASE; OXIDATIVE STRESS; PERMEABILITY; PLASMA; PRIORITY JOURNAL;

AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BRAIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IRON; IRON CHELATING AGENTS; NANOSTRUCTURES; PYRIDONES;

EID: 33748202940     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.07.020     Document Type: Article

References (29)

1. Bangs Laboratories Inc., TechNote #201, Working with microspheres, 1999.
2. Blake D.R., Winyard P., Lunec J., Williams A., Good P.A., Crewes S.J., Gutteridge J.M., Rowley D., Halliwell B., Cornish A., and Hider R.C. Cerebral and ocular toxicity induced by desferrioxamine. Q. J. Med 56 (1985) 345-355
3. Blunk T., Hochstrasser D.F., Sanchez J.C., Muller B.W., and Muller R.H. Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14 (1993) 1382-1387
4. Casdorph H.R. EDTA chelation therapy: efficacy in brain disorders. In: Cranton E.M. (Ed). A Textbook on EDTA Chelation Therapy (2001), Hamtpon Roads Publishing Company, Inc., Charlottesville 142-163
5. Crapper McLachlan D.R., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., and Andrews D.F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337 (1991) 1304-1308
6. Crowe A., and Morgan E.H. Effects of chelators on iron uptake and release by the brain in the rat. Neurochem. Res. 19 (1994) 71-76
7. Cui Z., Lockman P.R., Atwood C.S., Hsu C.H., Gupte A., Allen D.D., and Mumper R.J. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 59 (2005) 263-272
8. Davson H., and Segal M.B. Physiology of the CSF and Blood-Brain Barriers (1996), CRC Press 822 pp
9. Halliwell B., and Gutteridge J.M.C. Free Radicals in Biology and Medicine. 3rd ed. (1999), Oxford University Press
10. Hartig W., Paulke B.R., Varga C., Seeger J., Harkany T., and Kacza J. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer's disease. Neurosci. Lett. 338 (2003) 174-176
11. Hider R.C., and Hall A.D. Clinically useful chelators of tripositive elements. Prog. Med. Chem. 28 (1991) 41-173
12. Hider R.C., Porter J.B., and Singh S. The design of therapeutically useful iron chelators. In: Bergeron R.J., and Brittenham G.M. (Eds). The Development of Iron Chelators for Clinical Use (1994), CRC, Boca Raton 353-371
13. Kong S., Liochev S., and Fridovich I. Aluminum(III) facilitates the oxidation of NADH by the superoxide anion. Free Radic. Biol. Med. 13 (1992) 79-81
14. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
15. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., and Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target 10 (2002) 317-325
16. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., and Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158 (1998) 47-52
17. Lynch S.G., Fonseca T., and Levine S.M. A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol. Biol. (Noisy-le-grand) 46 (2000) 865-869
18. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23 (1997) 134-147
19. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107 (2006) 3436-3441
20. Olivieri N.F., and Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 89 (1997) 739-761
21. Perry G., Castellani R.J., Hirai K., and Smith M.A. Reactive oxygen species mediate cellular damage in Alzheimer disease. J. Alzheimer's Dis. 1 (1998) 45-55
22. Porter J.B., Morgan J., Hoyes K.P., Burke L.C., Huehns E.R., and Hider R.C. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 76 (1990) 2389-2396
23. Richardson D.R. The therapeutic potential of iron chelators. Expert Opin. Investig. Drugs 8 (1999) 2141-2158
24. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., and Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
25. Sayre L.M., Perry G., Harris P.L., Liu Y., Schubert K.A., and Smith M.A. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem. 74 (2000) 270-279
26. Sayre L.M., Perry G., and Smith M.A. Redox metals and neurodegenerative disease. Curr. Opin. Chem. Biol. 3 (1999) 220-225
27. Shea T.B., Ortiz D., Nicolosi R.J., Kumar R., and Watterson A.C. Nanosphere-mediated delivery of Vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta. J. Alzheimer's Dis. 7 (2005) 297-301
28. Smith M.A., Harris P.L., Sayre L.M., and Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94 (1997) 9866-9868
29. Smith M.A., Sayre L.M., Monnier V.M., and Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18 (1995) 172-176